Grufity logo
Grufity logo
ORGS

ORGS - Orgenesis Inc Stock Price, Fair Value and News

$0.40 
Market Closed as of 23 Oct 2026, 04:00 pm ET

ORGS Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ORGS Price Action

Last 7 days

566.7%

Last 30 days

-31.0%

Trailing 12 Months

-55.6%

ORGS RSI Chart

ORGS Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ORGS Valuation

Market Cap

3.9M

Price/Earnings (Trailing)

-0.08

Price/Sales (Trailing)

3.79

EV/EBITDA

-0.2

Price/Free Cashflow

-0.23

ORGS Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

ORGS Fundamentals

ORGS Revenue

Revenue (TTM)

1.0M

ORGS Earnings

Earnings (TTM)

-48.2M

ORGS Profitability

Operating Margin

-86.28%

EBT Margin

-4726.18%

Return on Equity

128.44%

Return on Assets

-3.6K%

Free Cashflow Yield

-442.34%

ORGS Investor Care

Revenue & Growth

How Orgenesis Inc generates revenue and covers its expenses, based on the latest reported earnings.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
2024529.0K662.0K899.0K1.0M
202327.2M18.3M9.4M530.0K
202233.3M30.0M29.3M36.0M
202115.2M24.0M30.9M35.5M
20204.9M6.0M6.5M7.7M
201913.7M11.3M8.8M3.9M
201813.5M15.2M16.9M18.7M
20176.7M7.9M8.6M10.1M
20163.8M4.7M5.5M6.4M
2015---3.0M
Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About Orgenesis Inc

ORGS
Orgenesis Inc., a biotech company, focusing on cell and gene therapies worldwide. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed POCare therapeutics that are processed and produced in closed automated POCare technology systems across a collaborative POCare network. It focuses on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient at their point of care for treatment of the patient. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is based in Germantown, Maryland.
 CEO
 WEBSITEorgenesis.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES167

Orgenesis Inc Frequently Asked Questions

ORGS is the stock ticker symbol of Orgenesis Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Oct 23 2026, market cap of Orgenesis Inc is 3.92 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Fri Oct 23 2026, ORGS's PE ratio (Price to Earnings) is -0.08 and Price to Sales (PS) ratio is 3.79. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ORGS PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Orgenesis Inc has provided -0.377 (multiply by 100 for percentage) rate of return.